{"id":60160,"date":"2025-07-10T20:13:40","date_gmt":"2025-07-10T20:13:40","guid":{"rendered":"https:\/\/cdhf.staging.not4prod.com\/?p=60160"},"modified":"2025-07-17T13:29:59","modified_gmt":"2025-07-17T13:29:59","slug":"the-evolving-age-of-biosimilars","status":"publish","type":"post","link":"https:\/\/cdhf.ca\/en\/the-evolving-age-of-biosimilars\/","title":{"rendered":"The Evolving Age of Biosimilars"},"content":{"rendered":"\n

Reviewed by Dr. Frank Hoentjen, MD PhD Professor of Medicine Director Inflammatory Bowel Disease Center<\/em><\/p>\n\n\n\n

In recent years, the availability of biosimilars has played a significant role in increasing access to biologic treatments, including those for inflammatory diseases such as, Crohn’s disease<\/a>, ulcerative colitis<\/a>, and rheumatoid arthritis.<\/p>\n\n\n\n

Biosimilars are biologic medications that are highly similar to the originator biologic in terms of structure, function, efficacy, and safety even though they may have slight differences due to the inherent complexity of biologic products.<\/p>\n\n\n\n

Regulatory bodies like Health Canada, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require biosimilars to demonstrate similarity to the reference biologic in terms of clinical efficacy, safety, and immunogenicity (the ability to make an immune response).<\/p>\n\n\n\n

Biosimilars and IBD<\/h2>\n\n\n\n

Being equivalent and less expensive versions of originator biologics, biosimilars offer expanding therapeutic approaches in the treatment of IBD. The reduced costs of biosimilars make IBD treatments more accessible to a wider range of patients, particularly those who may be limited by high drug prices.  This increased and improved accessibility to biologic therapies contributes to the long-term sustainability of healthcare systems.  <\/p>\n\n\n\n

\"nurse